

ArcticZymes Technologies Q4 2021 Results

Tromsø, Norway, 27th January 2022 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 40.5 million (22.1) and an EBITDA of NOK 20.8 million (6.8) for the fourth quarter of 2021.

Highlights from Q4 2021

- ArcticZymes Technologies (AZT) had Q4 sales of NOK 40.5 million – an increase of 84% (Q4 2020: NOK 22.1 million)
- Exceeded annual sales target achieving NOK 128.0 million for 2021 – an increase of 37% (2020: NOK 93.4 million)
- Coronavirus-related sales are estimated at NOK 9.3 million (Q4 2020: NOK 7.1 million)
- Gross profit increased to NOK 38.5 million because of increased sales (Q4 2020: NOK 21.5 million)
- Positive EBITDA of NOK 20.8 million (Q4 2020: NOK 6.8 million)
- Cash flow was positive NOK 14.0 million (Q4 2020: NOK 73.4 million due to Biotec BetaGlucans divestment) giving a cash balance of NOK 200.4 million (Q4 2020: NOK 140.2 million)
- Launched 3 new products and successfully upscaled the manufacturing of the M-SAN HQ enzyme
- New 500 m² production facility completed and operational

CEO Jethro Holter comments:

“We are delighted that the enzyme business continues to drive strong quarterly sales growth and exceeded its promise to achieve annual sales of NOK 120 million. It has been an excellent year for the Company demonstrating its ability to operate as a profitable and high-growth, standalone enzyme company following the earlier divestment of the Biotec BetaGlucans subsidiary.

ArcticZymes Technologies continues to bring innovations to market and enters 2022 with a new state-of-the art manufacturing facility. These will be instrumental in further supporting organic growth of the enzyme business.”

-Ends-

Fourth Quarter 2021 Presentation and Webcast

A presentation by ArcticZymes Technologies’ CEO, Jethro Holter will take place today, 27th January 2022, at 08:30 am as a live video/phone-conference.

Call in details: +47 21 40 24 87 with conference id: 141 573 333#. Participants who want to participate in the Teams webcast are asked to send an email to ir@arcticzymes.com for a separate invitation.

The results, report and presentation for the fourth quarter 2021 will be available on www.newsweb.no and on the Company’s homepage www.arcticzymes.com from 07:00 am on 27th January 2022.

For more information, please contact:**ArcticZymes Technologies ASA**

CEO, Jethro Holter
CFO, Børge Sørvoll

Tel: +47 46 85 91 46
Tel: +47 95 29 01 87
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec] ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.